TABLE OF CONTENTS

	Page No.
Abstract	i–ii
Preface	iii-iv
List of Tables	xi-xii
List of Figures	xiii-xxvi
List of Schemes	xxvii
List of Appendices	xxviii
Appendix A: List of Research Publications	xxix-xxx
Appendix B: Oral and Poster Presentations	xxxi
Abbreviation	xxxii-xxxiii

INTRODUCTION **1 - 52**

Brief introduction of two important aspects of lipidic components: lung surfactant and solid lipid nanoparticles as a novel drug delivery system

1. Fatty acids	**1**
2. General classification of lipid	**3**
2.1. Simple Lipids or Homolipids	**3**
2.1.1. Glycerides	**4**
2.1.2. Monoglyceride	**4**
2.1.3. Diglyceride	**4**
2.1.4. Triglyceride	**5**
2.1.5. Waxes	**6**
2.2. Compound Lipids or Heterolipids	**6**
2.2.1. Phospholipids (phosphatides)	**6**
2.2.2. Glycolipids (cerebrosides)	**7**
2.3. Derived Lipids	**8**
2.3.1. Steroids	**8**
2.3.2. Cholesterol	**8**
3. Lung surfactant (LS)	**9**
3.1. Composition of LS	**10**

3.2. Surfactant Proteins and Lung Disease **11**

3.3. Inhibition of LS in Disease **14**

3.4. Cholesterol Function in LS **15**

3.5. Serum Protein Role in ARDS **19**

3.6. LS and Interaction with Whole Fetal Calf Serum **21**

4. The interest in new drug delivery systems **24**

5. Drug delivery systems **25**

5.1. Nanocapsules and polymeric nanoparticles **25**

5.2. Liposomes **26**

5.3. Microemulsions and nanoemulsions **28**

6. Solid Lipid Nanoparticles **29**

6.1. Definitions and Physical Structure of Solid Lipid Nanoparticles **29**

6.2. Models for incorporation of active compounds into SLN **30**

6.2.1. Homogeneous model **30**

6.2.2. Drug-enriched shell model **31**

6.2.3. Drug-enriched core model **31**

7. Nanostructure Lipid Carriers **32**

7.1. Definitions and Physical Structure of Nanostructured Lipid **32**

7.2. Structure of Nanostructured Lipid Carriers **32**

7.2.1. NLC type I or “Imperfect crystal” type **32**

7.2.2. NLC type II or “Multiple” type **33**

7.2.3. NLC type III or “Amorphous” type NLC **33**

8. Preparation Techniques for Lipid Nanoparticles **34**

8.1. High Pressure Homogenization (HPH) **34**

8.2. Production of SLN via Microemulsions **35**

8.3. Preparation by Solvent Emulsification-Evaporation or –Diffusion **35**

8.4. Preparation by W/O/W Double Emulsion Method **36**

8.5. Preparation by High Speed Stirring and/or Ultrasonication **36**

9. Characterization of Nanostructured Lipid Carrier **37**

9.1. Dynamic Light Scattering **37**

9.2. Particle charge and zeta potential **39**

9.3. Morphology **40**

9.4. Crystallization **42**

9.5. Drug incorporation into SLN and NLC **44**

9.6. Controlled drug delivery **45**

10. Applications **47**

10.1. NLCs in brain delivery **48**

10.2. NLCs for topical delivery **48**

10.3. NLCs as cosmeceuticals **49**

10.4. NLCs as a targeted carrier for cancer **49**

10.5. Oral NLCs in anti-tubercular chemotherapy **50**

10.6. NLCs for potential applications in agriculture **50**

CHAPTER I **53 - 88**

Effect of Serum, Cholesterol and Low Density Lipoprotein on the Functionality and Structure of Lung Surfactant Films

1. Introduction **53**

2. Materials and methods **56**

2.1. Materials **56**

2.2. Lipid extraction of samples **57**

2.3. Methods **58**

2.3.1.Adsorption kinetics studies **58**

2.3.2. Langmuir surface balance studies **58**

2.3.3. Atomic force microscopy（AFM） **59**

2.3.4. Raman spectroscopy **60**

2.3.5. MALDI-TOF MS **61**

3. Results and discussion **61**

3.1.Composition of Serum and Surfactant **61**

3.2.Adsorption isotherms **63**

3.3.Langmuir surface balance studies **67**

3.4.Atomic force microscopy（AFM）Studies **72**

3.5.Raman spectroscopy studies **80**

4. Summary and conclusions **85**

5. References **88**

CHAPTER II **89 - 110**

Physicochemical studies on local anaesthetic loaded second generation nanolipid carriers

1. Introduction **89**

2. Materials and methods **93**

2.1.Materials **93**

2.2.Methods **94**

2.2.1. Preparation of NLCs **94**

2.2.2. Instrumentation **94**

3. Results and discussions **96**

3.1.DLS studies **96**

3.2.Transmission electron microscopy (TEM) study **99**

3.3. Differential scanning calorimetric (DSC) studies **100**

3.4. UV-visible absorption spectral studies **104**

3.5. Entrapment efficiency (EE) and loading content studies **106**

3.6.*In vitro* release kinetics **106**

4. Summary and conclusion **110**

5. References **110**

CHAPTER III **111 - 134**

Influence of lipid core material on physicochemical characteristics of ursolic acid loaded nanostructured lipid carrier: an attempt to enhance anticancer activity

1. Introduction **111**

2. Materials and methods **114**

2.1.Materials **114**

2.2.Methods **115**

2.3.*In - vitro* cytotoxicity study of UA-NLCs **117**

3. Results and discussion **117**

3.1.Interfacial behavior of the monomolecular films **117**

3.2.Dispersions / solution behavior of the NLCs **123**

3.2.1. Dynamic light scattering (DLS) studies **123**

3.3.Morphological studies **126**

3.4.Differential scanning calorimetric (DSC) studies **127**

3.5.Determination of UA entrapment efficiency and drug loading **131**

3.6.*In vitro* release kinetics of ursolic acid from NLC **131**

3.7.*In vitro* cytotoxicity studies **132**

4. Summary and conclusions **133**

5. References **134**

CHAPTER IV **135 - 158**

Oral administration of orcinol glucoside loaded polymer – lipid hybrid nanoparticles for gastrointestinal tract cancer targeting and improved *in vitro* cytotoxicity against GIT cell lines

1. Introduction **136**

2. Materials and methods **139**

2.1Materials **139**

2.2.Methods **140**

2.3.*In vitro* cytotoxicity study **141**

3. Results and discussion **141**

3.1.Disperions / solution behavior of the NLCs **141**

31.1. DLS Studies **141**

3.2.Morphology studies **145**

3.2.1. TEM, SEM and AFM Studies **145**

3.3.DSC investigations **147**

3.4.Drug entrapment efficiency and loading capacity **151**

3.5. *In vitro* release studies	**152**
3.6. *In vitro* cytotoxicity of OG-NLCs	**154**
4. Summary and conclusions	**158**
5. References	**158**
Summary and conclusion	**159 - 161**
Bibliographic References	
References for introduction	**162 – 173**
References for chapter I	**173 – 176**
References for chapter II	**176 – 179**
References for chapter III	**180 – 183**
References for chapter IV	**183 - 187**
Index	
Reprints	